The Safety/Efficacy Of Daratumumab With Belatacept In Highly HLA-Sensitized Patients Awaiting Kidney Transplantation
Stopped limited clinically significant reduction on global cPRA levels (access to transplantation was unchanged), as well as restrictions in belatacept supply.
Conditions
- Sensitisation
- Highly Sensitised Dialysis Patients
Interventions
- COMBINATION_PRODUCT: Each patient will undergo in the first step of the study belatacept treatment and in the second apheresis and daratumumab
Sponsor
University Hospital, Grenoble
Collaborators